PT-141 (Bremelanotide) Research Guide: Melanocortin Sexual Function Peptide

Research overview of PT-141 (Bremelanotide) — FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder (HSDD). Covers mechanism (MC3R/MC4R), approved dose (1.75mg intranasal), nausea management, comparison with PDE5 inhibitors, and research context.

TL;DR

• PT-141 = Bremelanotide = Vyleesi (FDA-approved for HSDD in premenopausal women since 2019)
• Mechanism: central MC3R/MC4R agonism in the brain — addresses desire/arousal, not just vascular function
• Approved dose: 1.75mg SubQ; research peptide doses range from 1-2mg
• Nausea (40%) is primary side effect; antiemetic pretreatment helps significantly
• Works in both men and women; not sex-specific despite initial HSDD indication

Disclaimer: For educational and research purposes only — not medical advice.

PT-141 (bremelanotide) has a unique history in peptide research — it was originally studied as a tanning peptide (a derivative of Melanotan I/II), where researchers unexpectedly observed potent sexual arousal effects during clinical trials. This serendipitous discovery led to its pharmaceutical development as a sexual dysfunction treatment, culminating in FDA approval in 2019 as Vyleesi — the first non-hormonal treatment for HSDD (Hypoactive Sexual Desire Disorder) in premenopausal women.

Melanocortin System Background

The melanocortin system includes five receptors (MC1R-MC5R) activated by melanocortin peptides (alpha-MSH, beta-MSH, ACTH, gamma-MSH). These receptors are distributed across skin, adrenal glands, and the central nervous system.

Relevant receptors for PT-141:

• MC3R: Hypothalamus and limbic system; involved in energy balance, reward, and sexual behavior
• MC4R: Widely distributed in CNS; critical for appetite regulation, sexual function, and autonomic nervous system regulation

MC4R and sexual function: MC4R activation in the paraventricular nucleus (PVN) and other hypothalamic regions initiates neural signaling cascades associated with sexual motivation, arousal, and genital response. This is the primary CNS target for PT-141's efficacy.

FDA Approval and Clinical Evidence

Vyleesi (1.75mg SubQ) was approved for premenopausal women with acquired, generalized HSDD in June 2019.

Key clinical trial data:

• RECONNECT trials: Primary endpoint met — significant improvement in "satisfying sexual events" (SSEs) vs placebo
• Female Sexual Function Index (FSFI): Significant improvements in desire and arousal domains
• Effect size moderate: ~1 additional satisfying sexual event per month vs placebo; meaningful to affected individuals but modest in absolute terms
• Response onset: 45 minutes to 1 hour; duration 12+ hours

Male research:

• PT-141 has been studied in erectile dysfunction with and without PDE5 inhibitor combination
• Men with ED who did not respond to Viagra showed responses to PT-141 — suggesting complementary mechanisms
• Research in healthy men shows increased sexual arousal and erectile function

Administration Routes

Intranasal PT-141 was used in early research — the first human studies used intranasal spray before SubQ was established as the more reliable route. Research community protocols vary between SubQ and intranasal.

Nausea Management Protocol

Nausea is the limiting side effect for many PT-141 researchers:

Prevention strategies:

The nausea typically peaks 1-2 hours post-injection and resolves within 2-4 hours. Most subjects who experience nausea find it manageable with antiemetic pretreatment.

Comparison: PT-141 vs. PDE5 Inhibitors

Combination research: PT-141 (central) + tadalafil (peripheral) has been researched and may produce complementary effects — addressing both desire/arousal (CNS) and vascular mechanics simultaneously.

Research Dosing Protocol

Frequently Asked Questions

Q: Does PT-141 cause hyperpigmentation? A: PT-141 activates MC1R (melanocyte stimulating hormone receptor), which promotes melanin production. This can cause transient darkening of existing moles, new skin pigmentation, and with chronic use, hyperpigmentation. This is the same mechanism by which Melanotan II (a related peptide) causes tanning. At the once-to-several times monthly dosing protocol, hyperpigmentation is minimal. Frequent users should monitor any changes in moles or skin pigmentation and use sun protection.

Q: Is PT-141 appropriate for men with normal erectile function? A: PT-141's primary indication is desire/arousal deficit rather than mechanical erectile dysfunction. Men with normal vascular function but reduced desire (low T, stress, relationship factors, anhedonia) may see relevant benefits. In men with adequate desire but ED specifically, PDE5 inhibitors are more directly mechanistically relevant. The combination (PT-141 for desire, PDE5 inhibitor for mechanics) addresses both dimensions in men with complex sexual dysfunction.

Use the Dosage Calculator → /calculators/dosage

For educational and research purposes only. Not medical advice.

Disclaimer: For educational and research purposes only. Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. All compounds discussed are research chemicals or investigational compounds unless explicitly noted otherwise. Consult a qualified healthcare professional before making any health-related decisions. Researchers must comply with all applicable laws and regulations in their jurisdiction.

Frequently Asked Questions